Huaan Securities Co.Ltd(600909) 04 released a research report on 27 April, saying that it maintained the buying rating of Teyi Pharmaceutical Group Co.Ltd(002728) ( Teyi Pharmaceutical Group Co.Ltd(002728) .sz, latest price: 12.36 yuan). The reasons for rating mainly include: 1) the profit side is affected by non recurring profit and loss, and the profit after deducting non recurring profit is higher than expected; 2) The cost side is obviously controlled, and the income side is expected to be affected by the epidemic; 3) Teyi Pharmaceutical Group Co.Ltd(002728) multiple varieties develop together, and the “1 + n” product line matrix is worth looking forward to. Risk warning: policy change risk; Risk of drug price reduction; Operational risk.
AI comments: Teyi Pharmaceutical Group Co.Ltd(002728) in the past month, it has received two research reports from securities companies and bought two.
